Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Antibiotic treatment failure in children aged 1 to 59 months with World Health Organization-defined severe pneumonia in Malawi: A CPAP IMPACT trial secondary analysis
by
Mtimaukanena, Takondwa A.
, Mvalo, Tisungane
, Kondowe, Davie
, Nansongole, Dan
, Eckerle, Michelle
, Liu, Yisi
, Smith, Andrew G.
, Vaidya, Dhananjay
, Corbett, Kelly
, Hosseinipour, Mina C.
, Lufesi, Norman
, McCollum, Eric D.
in
Age
/ Anti-Bacterial Agents - therapeutic use
/ Antibiotics
/ Bacterial pneumonia
/ Benzylpenicillin
/ Biology and Life Sciences
/ Ceftriaxone
/ Child
/ Child, Preschool
/ Children
/ Children & youth
/ Continuous positive airway pressure
/ Data collection
/ Diseases
/ Dosage and administration
/ Drug therapy
/ Edema
/ Etiology
/ Evaluation
/ Failure analysis
/ Gentamicin
/ Health care facilities
/ Health facilities
/ Health risks
/ Hemoglobin
/ HIV
/ Hospital facilities
/ Hospitalization
/ Hospitals
/ Human immunodeficiency virus
/ Humans
/ Hypoxemia
/ Impact analysis
/ Infant
/ Intravenous administration
/ Low income groups
/ Malaria
/ Malawi - epidemiology
/ Malnutrition
/ Malnutrition - complications
/ Medicine and Health Sciences
/ Mortality
/ Patient outcomes
/ Patients
/ Pediatrics
/ Physical Sciences
/ Pneumonia
/ Pneumonia - complications
/ Regression analysis
/ Regression models
/ Risk analysis
/ Risk factors
/ Secondary analysis
/ Streptococcus infections
/ Treatment Failure
/ Vaccines
/ World Health Organization
2022
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Antibiotic treatment failure in children aged 1 to 59 months with World Health Organization-defined severe pneumonia in Malawi: A CPAP IMPACT trial secondary analysis
by
Mtimaukanena, Takondwa A.
, Mvalo, Tisungane
, Kondowe, Davie
, Nansongole, Dan
, Eckerle, Michelle
, Liu, Yisi
, Smith, Andrew G.
, Vaidya, Dhananjay
, Corbett, Kelly
, Hosseinipour, Mina C.
, Lufesi, Norman
, McCollum, Eric D.
in
Age
/ Anti-Bacterial Agents - therapeutic use
/ Antibiotics
/ Bacterial pneumonia
/ Benzylpenicillin
/ Biology and Life Sciences
/ Ceftriaxone
/ Child
/ Child, Preschool
/ Children
/ Children & youth
/ Continuous positive airway pressure
/ Data collection
/ Diseases
/ Dosage and administration
/ Drug therapy
/ Edema
/ Etiology
/ Evaluation
/ Failure analysis
/ Gentamicin
/ Health care facilities
/ Health facilities
/ Health risks
/ Hemoglobin
/ HIV
/ Hospital facilities
/ Hospitalization
/ Hospitals
/ Human immunodeficiency virus
/ Humans
/ Hypoxemia
/ Impact analysis
/ Infant
/ Intravenous administration
/ Low income groups
/ Malaria
/ Malawi - epidemiology
/ Malnutrition
/ Malnutrition - complications
/ Medicine and Health Sciences
/ Mortality
/ Patient outcomes
/ Patients
/ Pediatrics
/ Physical Sciences
/ Pneumonia
/ Pneumonia - complications
/ Regression analysis
/ Regression models
/ Risk analysis
/ Risk factors
/ Secondary analysis
/ Streptococcus infections
/ Treatment Failure
/ Vaccines
/ World Health Organization
2022
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Antibiotic treatment failure in children aged 1 to 59 months with World Health Organization-defined severe pneumonia in Malawi: A CPAP IMPACT trial secondary analysis
by
Mtimaukanena, Takondwa A.
, Mvalo, Tisungane
, Kondowe, Davie
, Nansongole, Dan
, Eckerle, Michelle
, Liu, Yisi
, Smith, Andrew G.
, Vaidya, Dhananjay
, Corbett, Kelly
, Hosseinipour, Mina C.
, Lufesi, Norman
, McCollum, Eric D.
in
Age
/ Anti-Bacterial Agents - therapeutic use
/ Antibiotics
/ Bacterial pneumonia
/ Benzylpenicillin
/ Biology and Life Sciences
/ Ceftriaxone
/ Child
/ Child, Preschool
/ Children
/ Children & youth
/ Continuous positive airway pressure
/ Data collection
/ Diseases
/ Dosage and administration
/ Drug therapy
/ Edema
/ Etiology
/ Evaluation
/ Failure analysis
/ Gentamicin
/ Health care facilities
/ Health facilities
/ Health risks
/ Hemoglobin
/ HIV
/ Hospital facilities
/ Hospitalization
/ Hospitals
/ Human immunodeficiency virus
/ Humans
/ Hypoxemia
/ Impact analysis
/ Infant
/ Intravenous administration
/ Low income groups
/ Malaria
/ Malawi - epidemiology
/ Malnutrition
/ Malnutrition - complications
/ Medicine and Health Sciences
/ Mortality
/ Patient outcomes
/ Patients
/ Pediatrics
/ Physical Sciences
/ Pneumonia
/ Pneumonia - complications
/ Regression analysis
/ Regression models
/ Risk analysis
/ Risk factors
/ Secondary analysis
/ Streptococcus infections
/ Treatment Failure
/ Vaccines
/ World Health Organization
2022
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Antibiotic treatment failure in children aged 1 to 59 months with World Health Organization-defined severe pneumonia in Malawi: A CPAP IMPACT trial secondary analysis
Journal Article
Antibiotic treatment failure in children aged 1 to 59 months with World Health Organization-defined severe pneumonia in Malawi: A CPAP IMPACT trial secondary analysis
2022
Request Book From Autostore
and Choose the Collection Method
Overview
Pneumonia is a leading cause of mortality in children <5 years globally. Early identification of hospitalized children with pneumonia who may fail antibiotics could improve outcomes. We conducted a secondary analysis from the Malawi CPAP IMPACT trial evaluating risk factors for antibiotic failure among children hospitalized with pneumonia.
Participants were 1-59 months old with World Health Organization-defined severe pneumonia and hypoxemia, severe malnutrition, and/or HIV exposure/infection. All participants received intravenous antibiotics per standard care. First-line antibiotics were benzylpenicillin and gentamicin for five days. Study staff assessed patients for first-line antibiotic failure daily between days 3-6. When identified, patients failing antibiotics were switched to second-line ceftriaxone. Analyses excluded children receiving ceftriaxone and/or deceased by hospital day two. We compared characteristics between patients with and without treatment failure and fit multivariable logistic regression models to evaluate associations between treatment failure and admission characteristics.
From June 2015-March 2018, 644 children were enrolled and 538 analyzed. Antibiotic failure was identified in 251 (46.7%) participants, and 19/251 (7.6%) died. Treatment failure occurred more frequently with severe malnutrition (50.2% (126/251) vs 28.2% (81/287), p<0.001) and amongst those dwelling ≥10km from a health facility (22.3% (56/251) vs 15.3% (44/287), p = 0.026). Severe malnutrition occurred more frequently among children living ≥10km from a health facility than those living <10km (49.0% (49/100) vs 35.7% (275/428), p = 0.014). Children with severe malnutrition (adjusted odds ratio (aOR) 2.2 (95% CI 1.52, 3.24), p<0.001) and pre-hospital antibiotics ((aOR 1.47, 95% CI 1.01, 2.14), p = 0.043) had an elevated aOR for antibiotic treatment failure.
Severe malnutrition and pre-hospital antibiotic use predicted antibiotic treatment failure in this high-risk severe pneumonia pediatric population in Malawi. Our findings suggest addressing complex sociomedical conditions like severe malnutrition and improving pneumonia etiology diagnostics will be key for better targeting interventions to improve childhood pneumonia outcomes.
Publisher
Public Library of Science,Public Library of Science (PLoS)
This website uses cookies to ensure you get the best experience on our website.